These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31919889)

  • 1. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
    Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
    Thaci D; Piaserico S; Warren RB; Gupta AK; Cantrell W; Draelos Z; Foley P; Igarashi A; Langley RG; Asahina A; Young M; Falqués M; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Reich K
    Br J Dermatol; 2021 Aug; 185(2):323-334. PubMed ID: 33544883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
    Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
    Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials.
    Kerbusch T; Li H; Wada R; Jauslin PM; Wenning L
    Br J Clin Pharmacol; 2020 Sep; 86(9):1795-1806. PubMed ID: 32162721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
    Gordon KB; Reich K; Crowley JJ; Korman NJ; Murphy FT; Poulin Y; Spelman L; Yamauchi PS; Mendelsohn AM; Parno J; Rozzo SJ; Ellis CN
    J Dermatolog Treat; 2022 Feb; 33(1):219-228. PubMed ID: 32349565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
    Lebwohl MG; Leonardi CL; Mehta NN; Gottlieb AB; Mendelsohn AM; Parno J; Rozzo SJ; Menter MA
    J Am Acad Dermatol; 2021 Feb; 84(2):398-407. PubMed ID: 32961255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [No Abstract]   [Full Text] [Related]  

  • 13. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
    Warren RB; Carrascosa JM; Fumero E; Schoenenberger A; Lebwohl MG; Szepietowski JC; Reich K
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):919-927. PubMed ID: 32979235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
    Fernandez AP; Dauden E; Gerdes S; Lebwohl MG; Menter MA; Leonardi CL; Gooderham M; Gebauer K; Tada Y; Lacour JP; Bianchi L; Egeberg A; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Mehta NN
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1774-1783. PubMed ID: 35460287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2.
    Dykukha I; Schoenenberger A; Kasujee I; Mrowietz U; Vonthein R
    Dermatology; 2022; 238(5):910-918. PubMed ID: 35168231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.
    Thaçi D; Gerdes S; Du Jardin KG; Perrot JL; Puig L
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2325-2341. PubMed ID: 36098877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
    J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.